Cargando…
A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo
Jumonji C-domain-containing protein 6 (JMJD6), an iron (Fe(2+)) and α-ketoglutarate (α-KG)-dependent oxygenase, is expressed at high levels, correlated with poor prognosis, and considered as a therapeutic target in multiple cancer types. However, specific JMJD6 inhibitors that are potent in suppress...
Autores principales: | Xiao, Rong-quan, Ran, Ting, Huang, Qi-xuan, Hu, Guo-sheng, Fan, Da-meng, Yi, Jia, Liu, Wen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407455/ https://www.ncbi.nlm.nih.gov/pubmed/35969736 http://dx.doi.org/10.1073/pnas.2200753119 |
Ejemplares similares
-
Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo
por: Tarnowski, Maciej, et al.
Publicado: (2017) -
Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression
por: Wang, Panxia, et al.
Publicado: (2020) -
EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
por: Xia, Lin, et al.
Publicado: (2020) -
The histone demethylase JMJD2B regulates endothelial-to-mesenchymal transition
por: Glaser, Simone F., et al.
Publicado: (2020) -
Widespread hydroxylation of unstructured lysine-rich protein domains by JMJD6
por: Cockman, Matthew E., et al.
Publicado: (2022)